Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
3.370
+0.030 (0.90%)
At close: Mar 9, 2026, 4:00 PM EDT
3.330
-0.040 (-1.19%)
After-hours: Mar 9, 2026, 7:00 PM EDT
Fortress Biotech Employees
Fortress Biotech had 101 employees as of December 31, 2024. The number of employees decreased by 85 or -45.70% compared to the previous year.
Employees
101
Change (1Y)
-85
Growth (1Y)
-45.70%
Revenue / Employee
$616,861
Profits / Employee
-$52,832
Market Cap
104.60M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 101 | -85 | -45.70% |
| Dec 31, 2023 | 186 | -1 | -0.53% |
| Dec 31, 2022 | 187 | 14 | 8.09% |
| Dec 31, 2021 | 173 | 62 | 55.86% |
| Dec 31, 2020 | 111 | 18 | 19.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Agenus | 316 |
| Codexis | 188 |
| Seer, Inc. | 134 |
| Korro Bio | 87 |
| Precision BioSciences | 67 |
| Biomea Fusion | 42 |
| Equillium | 35 |
| Cassava Sciences | 30 |
FBIO News
- 14 days ago - UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 14 days ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 14 days ago - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease - GlobeNewsWire
- 7 weeks ago - Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States - GlobeNewsWire
- 3 months ago - Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - GlobeNewsWire
- 3 months ago - Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewsWire
- 4 months ago - Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 4 months ago - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire